Effect of Low-Dose Radiotherapy on the Circulating Levels of Paraoxonase-1-Related Variables and Markers of Inflammation in Patients with COVID-19 Pneumonia

• Main Authors: Elisabet Rodríguez-Tomàs (Author), Johana C. Acosta (Author), Laura Torres-Royo (Author), Gabriel De Febrer (Author), Gerard Baiges-Gaya (Author), Helena Castañé (Author), Andrea Jiménez (Author), Carlos Vasco (Author), Pablo Araguas (Author), Junior Gómez (Author), Bárbara Malave (Author), Miguel Árquez (Author), David Calderón (Author), Berta Piqué (Author), Manel Algara (Author), Ángel Montero (Author), Josep M. Simó (Author), Xavier Gabaldó-Barrios (Author), Sebastià Sabater (Author), Jordi Camps (Author), Jorge Joven (Author), Meritxell Arenas (Author)
• Format: Book
• Published: MDPI AG, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary

The aim of our study was to investigate the changes produced by low-dose radiotherapy (LDRT) in the circulating levels of the antioxidant enzyme paraoxonase-1 (PON1) and inflammatory markers in patients with COVID-19 pneumonia treated with LDRT and their interactions with clinical and radiological changes. Data were collected from the IPACOVID prospective clinical trial (NCT04380818). The study included 30 patients treated with a whole-lung dose of 0.5 Gy. Clinical follow-up, as well as PON1-related variables, cytokines, and radiological parameters were analyzed before LDRT, at 24 h, and 1 week after treatment. Twenty-five patients (83.3%) survived 1 week after LDRT. Respiratory function and radiological images improved in survivors. Twenty-four hours after LDRT, PON1 concentration significantly decreased, while transforming growth factor beta 1 (TGF-β1) increased with respect to baseline. One week after LDRT, patients had increased PON1 activities and lower PON1 and TGF-β1 concentrations compared with 24 h after LDRT, PON1 specific activity increased, lactate dehydrogenase (LDH), and C-reactive protein (CRP) decreased, and CD4+ and CD8+ cells increased after one week. Our results highlight the benefit of LDRT in patients with COVID-19 pneumonia and it might be mediated, at least in part, by an increase in serum PON1 activity at one week and an increase in TGF-β1 concentrations at 24 h.

Item Description

10.3390/antiox11061184
2076-3921